Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-11-01
2003-01-07
Fan, Jane (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S344000
Reexamination Certificate
active
06503917
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to novel substituted pyridine compounds having estrogenic activity, to processes for their preparation, to combinatorial and solid phase methods for preparing libraries of the compounds, to utilizing libraries of the compounds for drug discovery, to methods of treatment and to pharmaceutical compositions thereof.
BACKGROUND OF THE INVENTION
The solid phase synthesis. of non-peptidic small organic molecules is a rapidly evolving area of research with applications in the preparation of combinatorial libraries. While the solid phase synthesis of peptides is an established, the solid phase synthesis of non-peptidic small organic molecules is still evolving (Hermkens, P. H. H.; Ottenheijm, H. C. J.; Rees, D.
Tetrahedron
1996, 52, 4527-4554). In particular, methods for the solid phase synthesis of heterocyclic ring systems of importance to drug discovery is an active area of research.
Pyridine derivatives are commonly used as pharmaceuticals (Gordeev, M. F., et al.
Tetrahedron Lett.,
1996, 37, 4643-4646). Trisubstituted pyridines are a useful class of compounds. Karle, et al. (
Antimicrob. Agents Chemother.
1989, 33, 1081-1089) describe 2,4,6-trisubstituted pyridines as antiprotozoal agents. Shirai, et al. (WO 96/00213) describe 2,4,6-trisubstituted pyridines as useful for accelerating nerve growth factor production, and also ((WO 96/16942) as useful for ameliorating neuropathy.
Combinatorial chemistry is becoming an important tool for drug discovery and lead optimization (Borman, S.
Chemical and Engineering News
1997, 75 (8), 43-62). A combinatorial synthesis requires that at least two components of the product molecules be independently variable, so that all of the combinations of these components can be prepared. A synthesis with three independently variable components is preferable since greater diversity in structure can be produced in the resultant library. Thus, to prepare a combinatorial library of pyridines with a high degree of potential diversity and wide utility for drug discovery using solid phase techniques, it is important to identify a pyridine synthesis in which three components can be independently varied. The solution phase synthesis of pyridines from 1,5-pentanediones and ammonia followed by oxidation is known (Katritzky, A. R. Handbook of
Heterocyclic Chemistry,
pp. 408-409; Pergamon Press: Oxford, 1985). A variation of this synthesis involves the reaction of a bromomethyl ketone with pyridine, and subsequent reaction of this intermediate with an unsaturated ketone in the presence of ammonium acetate in acetic acid to yield a 2,4,6-trisubstituted pyridine (Krohnke, F.
Synthesis
1976, 1-24). The latter synthesis proceeds through a 1,5-diketone intermediate which is not isolated. For a solid phase combinatorial synthesis it is necessary to modify these syntheses to allow for the independent introduction of three variables (the 2,4, and 6 substituents), and to adapt the solution phase synthesis to a solid supported synthesis. The solid phase pyridine synthesis of this invention is achieved by using a hydroxyacetophenone starting material which can be attached to a solid support through the phenolic hydroxy group.
A solid phase synthesis of 2,3,4,5,6-pentasubstituted dihydropyridines and pyridines has been described in Gordeev, M. F., et al.
Tetrahedron Lett.,
1996, 37, 4643-4646. The compounds are prepared by the Hantzsch pyridine synthesis and therefore all contain acyl or carboxyl groups in the 3- and 5-positions. The solid phase synthesis of the current invention does not yield pyridines with acyl or carboxyl groups in the 3-and 5-position of all products and therefore yields a more diverse set of products.
Multiple compounds can be prepared simultaneously by the solid phase process. The simultaneous solid phase synthesis of a library of 2,4,6-trisubstituted pyridines of the present invention is not known. The preparation of libraries of compounds of the present invention is useful because it provides rapid structural variation and structure-activity information.
The libraries of substituted pyridines synthesized according to the present invention are useful for drug discovery. Screening of the pyridine libraries in an estrogen receptor assay identified compounds with estrogen agonist activity. Estrogen agonists are useful as post-menopausal therapeutics for the prevention and treatment of osteoporosis, atherosclerosis, and Alzheimer's disease.
SUMMARY OF THE INVENTION
The present invention relates to new compounds selected from those of the general Formula (I) and also discloses a solid phase synthesis process for producing new compounds selected from those of Formula (I):
wherein:
the moiety Z
is selected from the group:
n is an integer of 1 or 2;
R
1
is straight chain alkyl of 1 to 6 carbon atoms, branched chain alkyl of 3 to 7 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl, or phenyl substituted with fluoro, chloro, bromo, straight chain alkyl of 1 to 6 carbon atoms, branched chain alkyl of 3 to 7 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl, alkoxy of 1 to 6 carbon atoms, or methylenedioxy;
R
2
is furanyl, pyridyl, thienyl, naphthalenyl, phenyl, or phenyl substituted with fluoro, chloro, bromo, straight chain alkyl of 1 to 6 carbon atoms, branched chain alkyl of 3 to 7 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, alkoxy of 1 to 6 carbon atoms, or methylenedioxy;
R
3
is hydrogen, fluoro, chloro, bromo, nitro, straight chain alkyl of 1 to 6 carbon atoms, branched chain alkyl of 3 to 7 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, or alkoxy of 1 to 6 carbon atoms; and all crystalline forms and the pharmaceutically acceptable salts thereof, the enantiomers thereof, the racemic mixtures thereof, and the diastereomeric mixtures thereof.
Among the preferred groups of compounds of this invention are those in the subgroups:
a) compounds having the general formula:
wherein R
1
, R
2
, and R
3
are as defined above or a pharmaceutically acceptable salt;
b) compounds having the general formula:
wherein R
1
, R
2
, R
3
and n are as defined above or a pharmaceutically acceptable salt.
Among the more preferred compounds of this invention are those of the formula:
wherein R
1
, R
2
, and R
3
are as defined above or a pharmaceutically acceptable salt.
The most particularly preferred compounds of Formula (I) of the present invention prepared by the herein described solid phase synthesis processes are:
2-[6-(4-chloro-phenyl)-4-(3,4-difluoro-phenyl)-pyridin-2-yl]-phenol or a pharmaceutically acceptable salt thereof;
2-[4-(3,4-difluoro-phenyl)-6-naphthalen-2-yl-pyridin-2-yl]-phenol or a pharmaceutically acceptable salt thereof;
2-[4-(3,4-difluoro-phenyl)-6-furan-2-yl-pyridin-2-yl]-phenol or a pharmaceutically acceptable salt thereof;
2-(4-benzo[1,3]dioxol-5-yl-6-naphthalen-2-yl-pyridin-2-yl)-phenol or a pharmaceutically acceptable salt thereof;
2-(4-benzo[1,3]dioxol-5-yl-6-thiophen-3-yl-pyridin-2-yl)-phenol or a pharmaceutically acceptable salt thereof;
2-(4-biphenyl-4-yl-6-naphthalen-2-yl-pyridin-2-yl)-4-fluoro-phenol or a pharmaceutically acceptable salt thereof;
2-(4-biphenyl-4-yl-[2,4′]bipyridinyl-6-yl)-4-fluoro-phenol or a pharmaceutically acceptable salt thereof;
2-(4-cyclohexyl-6-furan-2-yl-pyridin-2-yl)-4-fluoro-phenol or a pharmaceutically acceptable salt thereof;
3-(4-biphenyl-4-yl-6-naphthalen-2-yl-pyridin-2-yl)-phenol or a pharmaceutically acceptable salt thereof;
3-(4-cyclohexyl-6-furan-2-yl-pyridin-2-yl)-phenol or a pharmaceutically acceptable salt thereof.
The novel process for producing novel compounds of Formula (I) comprises the steps of:
a) attaching a hydroxyacetophenone 1 of the formula
or an alkaline metal salt thereof where the moiety Z and R
3
are hereinbefore defined,to a solid support to produce an acetophenone 2
wherein the moiety Z and R
3
are hereinbefore defined, R
4
and R
5
are independently hydrogen or methoxy, and P is preferably a polystyrene resin
Chiu Chingfan
Ellingboe John W.
Tang Zhilian
Fan Jane
Moran Daniel B.
Wyeth, Five Giralda Farms
LandOfFree
2,4,6-trisubstituted pyridines with estrogenic activity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,4,6-trisubstituted pyridines with estrogenic activity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4,6-trisubstituted pyridines with estrogenic activity and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3036912